Clinical trials
Resectable Non-small Cell Lung Cancer clinical trials
Below are recruiting resectable non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 355 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07227298RecruitingPhase 1/Phase 2
Study of new drug combo for advanced lung cancer
This study tests a new combination of cancer drugs (PF-08634404 with other anticancer agents) for people with advanced non-small cell lung cancer who have not yet received any treatment for their advanced disease. It aims to see if this combination can shrink tumors or slow cancer growth.
Fayetteville, ArkansasAges 18 years+ - NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT06758401RecruitingPhase 3
Sigvotatug vedotin plus pembrolizumab for advanced lung cancer with high PD-L1
This trial tests a new combination of two study medicines for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see if adding sigvotatug vedotin to pembrolizumab works better than pembrolizumab alone.
Fullerton, CaliforniaAges 18 years+ - NCT06088771RecruitingPhase 1/Phase 2
Study of dupilumab and cemiplimab before lung cancer surgery
This study tests two drugs, dupilumab and cemiplimab, given before surgery for early-stage lung cancer. The goal is to see if these immune-boosting medicines can shrink the tumor and improve outcomes.
New York, New YorkAges 18 years+ - NCT06899126RecruitingPhase 3
Study of a drug combo for first-line HER2-positive lung cancer
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
Anchorage, AlaskaAges 18 years+ - NCT06529822RecruitingPhase 1
Personalized cancer vaccine for solid tumors with MRD
This trial tests a personalized cancer vaccine for people with certain cancers (bladder, stomach/esophagus, melanoma, or lung) who have no visible cancer after surgery but still have tiny bits of cancer DNA in their blood (called MRD). The vaccine is designed to train your immune system to attack any remaining cancer cells.
Orlando, FloridaAges 18 years+ - NCT07405190RecruitingPhase 2
Ivonescimab with or without chemo for advanced NSCLC
This study tests a new drug, ivonescimab, alone or with chemotherapy (carboplatin and pemetrexed), for people with advanced lung cancer that has specific gene changes and has already been treated with targeted therapy. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Boston, MassachusettsAges 18 years+ - NCT03808337RecruitingPhase 2
SBRT radiation plus standard treatment for spread cancer
This trial looks at adding a focused radiation treatment called SBRT to standard care for cancers that have spread to a limited number of spots. It aims to control those spread-out tumors while still using the usual cancer treatment plan.
San Carlos, CaliforniaAges 18 years+ - NCT03953144RecruitingPhase 1/Phase 2
3D lung surgery planning with a dye to find tumors
This trial tests a new way to plan and guide lung cancer surgery using a special dye that shows the tumor area during the operation. It may help surgeons remove the cancer more accurately while targeting only a small section of lung for certain early-stage patients.
Hamilton, OntarioAges 18 years+ - NCT04147078RecruitingPhase 1
Personalized immune vaccine after surgery for certain cancers
This Phase 1 study tests a personalized vaccine made for you to help your immune system after you’ve had surgery or ablation for certain cancers. It’s mainly done to check safety and see how well the vaccine can work at preventing cancer from coming back.
Chengdu, SichuanAges 18–100 - NCT04302025RecruitingPhase 2
Testing targeted and immunotherapy before lung cancer surgery
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
Duarte, CaliforniaAges 18 years+ - NCT04317534RecruitingPhase 2
Pembrolizumab after lung cancer surgery versus observation
This trial tests whether pembrolizumab (an immunotherapy drug) given after complete surgery can lower the chance that early-stage lung cancer comes back. You’ll be compared to standard follow-up without extra treatment to see if the drug helps more people stay cancer-free.
Tampa, FloridaAges 18 years+ - NCT04322578RecruitingPhase 2
Crizotinib versus standard chemotherapy for MET exon 14 lung cancer
This study compares crizotinib to standard chemotherapy for people with advanced (spread) non-small cell lung cancer that has a specific change called MET exon 14 skipping. The goal is to see which treatment works better and how safely it controls the cancer.
Changsha, HunanAges 18 years+ - NCT04324151Recruiting
Pembrolizumab plus chemotherapy for lung cancer that may be removed
This trial tests whether adding pembrolizumab (an immune therapy) to standard chemotherapy helps people with certain non-squamous lung cancers that doctors think might be surgically removed. You might be considered if your planned treatment involves a “double platinum” chemotherapy or crizotinib and your cancer is potentially resectable.
Changsha, HunanAges 18 years+ - NCT04322617RecruitingPhase 2/Phase 3
Anlotinib plus immunotherapy for lung cancer after first treatment
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
Changsha, HunanAges 18 years+ - NCT04335292RecruitingPhase 2
Osimertinib then chemotherapy for EGFR-mutated lung cancer
This Phase 2 study tests a treatment sequence starting with osimertinib, then using chemotherapy after it. It is meant for people with EGFR-mutated advanced lung cancer whose disease has come back or progressed, including a “rechallenge” attempt with osimertinib.
Vancouver, British ColumbiaAges 18 years+ - NCT04410796RecruitingPhase 2
Osimertinib alone or with chemo for EGFR-mutant lung cancer
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Sacramento, CaliforniaAges 18 years+ - NCT04550104RecruitingPhase 1
Durvalumab with radiation for lung cancer patients
This trial tests adding durvalumab (an immune therapy) to a radiation treatment plan for people with non-small cell lung cancer (NSCLC) who can’t safely have chemotherapy at the same time or surgery first. It aims to improve cancer control after radiation by helping the immune system recognize and fight the tumor.
BelfastAges 18 years+ - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Scottsdale, ArizonaAges 18 years+ - NCT04789486RecruitingPhase 1/Phase 2
MR-guided radiation plus nanoparticles for central lung or pancreatic tumors
This early-phase study tests a new way to deliver focused radiation using MRI guidance and tiny particles, aiming to treat certain central lung tumors or locally advanced pancreatic cancer. It’s designed to see how safe it is and how well it can control these tumors.
Boston, MassachusettsAges 18 years+ - NCT05628376Recruiting
Tracking lung cancer evolution through treatment
This study follows people with lung cancer over time to see how the disease changes, especially during and after treatment. By collecting tumor samples and blood tests every few months, researchers hope to understand why some cancers come back or become resistant, and find better ways to treat them.
LondonAges 18 years+ - NCT04944563Recruiting
Segmentectomy vs lobectomy for small middle-lung lung cancer
This trial compares two types of lung surgery for certain small lung cancers in the middle part of the lung: removing a segment (segmentectomy) versus removing a whole lobe (lobectomy). It aims to see which surgery works better while balancing cancer control and lung function.
Nanjing, JiangsuAges 18–75 - NCT04973293Recruiting
Pre-surgery immunotherapy plus chemo and blood-vessel medicine for lung cancer
This study tests whether giving sintilimab (an immune therapy) combined with bevacizumab (a blood-vessel–targeting medicine) plus chemotherapy before surgery can improve outcomes for resectable lung cancer. It’s meant for people with specific lung cancer types and good health for surgery, and it avoids certain cancer types and immune-related risks.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04991025RecruitingPhase 2
Certolizumab added to chemo and nivolumab for operable lung cancer
This Phase 2 study tests whether adding certolizumab (an immune-targeting medicine) to standard chemo plus nivolumab can improve outcomes in people with certain operable non-small cell lung cancers. The goal is to see if this combination works better than standard treatment before surgery.
Basking Ridge, New JerseyAges 18 years+
Hear when a new Resectable Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resectable non-small cell lung cancer?
- Yes. Clin2 currently lists 355 recruiting resectable non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resectable non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resectable non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.